Biomarkers of Aging Conference aims to move needle on clinical use of biomarkers, with focus on translation, validation and standardization.
Antiaging treatments are on the verge of becoming commercially available, but the field still lacks standardized, clinically validated tools to accurately measure the aging process and assess the impact of interventions that aim to extend healthspan and lifespan. Establishing these standards is critical to understanding the biology of aging and ensuring the safety and success of future innovations, and as research advances, the need for reliable measurement tools grows, highlighting the importance of collaboration across disciplines. It is a good thing, then, that the Biomarkers of Aging Conference will shortly be upon us.
Longevity.Technology: The Biomarkers of Aging Consortium’s upcoming event at Harvard Medical School addresses this need by bringing together leading scientists and industry experts to explore advancements in aging biomarkers and longevity interventions. This gathering fosters interdisciplinary collaboration, with sessions covering bioinformatics, open-source data sharing and innovative challenges (not to mention an interesting n=audience study!).
Through impactful discussions, the event aims to set new standards and advance research applications that could transform the management of aging and healthspan, bridging academic insights with practical applications for accelerated progress in the field. We sat down with two of the Consortium‘s Executive Committee, Drs Jesse Poganik and Mahdi Moqri to find out more.
“Translational aspect of biomarkers have been a focus from day one; these biomarkers are already being used in clinical trials, and the goal of the consortium as a whole and these large events is to bring different parties and learn how we can validate them, how we can standardize them, and how we can make them more reliable.”
“The Consortium is running a study to essentially biobank data specifically for the purpose of studying aging and longevity samples collected longitudinally over time. We’re making all the protocol documents and instruments that we’re using open source and freely available, and as we learn and develop standards that will be useful for the fields, we hope that others will adopt this as well.”
“One of the big goals of the Consortium is consensus building and the types of biomarkers that we’re primarily focused on, composite omics-based biomarkers, are very different from what is routinely used in the clinic now. But. things are changing and will continue to change, and the Consortium and the Conference as a way to bridge two worlds that ultimately need to be bridged for us to achieve the common goal of making these tools clinically useful.”
The Biomarkers of Aging Conference runs 1st & 2nd November at The Joseph B Martin Conference Center, Harvard Medical School, Boston, Massachusetts.
